Advanced
  Home Compare Reports

Comparison with Similar Reports

Clinical Trial Imaging Market by Software & Services(Operational Imaging, Read Analysis), Modality(CT, MRI, X-ray, PET, Ultrasound, ECHO), Therapeutic...

Publisher:        MarketsandMarkets

# of Pages:        199

Rating: 

1 User License $4,950

Publication Date:  July, 2021

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 33
1.2.2 MARKETS COVERED 34
FIGURE 1 CLINICAL TRIAL IMAGING MARKET SEGMENTATION 34
1.2.3 YEARS CONSIDERED FOR THE STUDY 34
1.3 CURRENCY 35
1.4 LIMITATIONS 35
1.5 STAKEHOLDERS 35
1.6 SUMMARY OF CHANGES 35
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
2.2 RESEARCH APPROACH 37
FIGURE 2 CLINICAL TRIAL IMAGING MARKET: RESEARCH DESIGN 37
2.2.1 SECONDARY DATA 38
2.2.1.1 Key data from secondary sources 38
2.2.2 PRIMARY DATA 39
2.2.2.1 Key data from primary sources 39
2.2.2.2 Key industry insights 40
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 41
2.3 MARKET SIZE ESTIMATION 41
2.3.1 BOTTOM-UP APPROACH 41
FIGURE 4 CLINICAL TRIAL IMAGING MARKET: BOTTOM-UP APPROACH 42
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
2.3.2 TOP-DOWN APPROACH 42
FIGURE 6 CLINICAL TRIAL IMAGING MARKET: TOP-DOWN APPROACH 42
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 43
FIGURE 7 DATA TRIANGULATION METHODOLOGY 43
2.5 ASSUMPTIONS FOR THE STUDY 44
2.6 GROWTH RATE ASSUMPTIONS 44
2.7 LIMITATIONS 45
2.8 RISK ASSESSMENT 45
2.9 COVID-19 HEALTH ASSESSMENT 45
2.10 COVID-19 ECONOMIC ASSESSMENT 46
2.10.1 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 46
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY 46
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 47
2.10.2 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE CLINICAL TRIAL IMAGING MARKET 48
3 EXECUTIVE SUMMARY 49
FIGURE 10 CLINICAL TRIAL IMAGING MARKET, BY PRODUCT AND SERVICE,
2021 VS. 2026 (USD MILLION) 49
FIGURE 11 CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2021 VS. 2026 (USD MILLION) 50
FIGURE 12 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2021 VS. 2026 (USD MILLION) 50
FIGURE 13 CLINICAL TRIAL IMAGING MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 51
FIGURE 14 CLINICAL TRIAL IMAGING MARKET, BY REGION,
2021 VS. 2026 (USD MILLION) 51
4 PREMIUM INSIGHTS 53
4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW 53
FIGURE 15 INCREASE IN R&D SPENDING TO DRIVE MARKET GROWTH 53
4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026 53
FIGURE 16 SERVICES WILL CONTINUE TO DOMINATE THE MARKET IN 2026 53
4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2021 VS. 2026 54
FIGURE 17 COMPUTED TOMOGRAPHY TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 54
4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2021 VS. 2026 54
FIGURE 18 ONCOLOGY IS THE LARGEST SEGMENT IN THE CLINICAL TRIAL IMAGING MARKET BY THERAPEUTIC AREA 54
4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2021 VS. 2026 55
FIGURE 19 PHARMACEUTICAL COMPANIES FORM THE LARGEST END USERS OF THE CLINICAL TRIAL IMAGING MARKET 55
4.6 CLINICAL TRIAL IMAGING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE CLINICAL TRIAL IMAGING MARKET DURING THE FORECAST PERIOD 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 21 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.2.1 DRIVERS 57
5.2.1.1 Increasing R&D spending 57
5.2.1.2 Growth in the pharmaceutical and biotechnology industries 57
5.2.1.3 Increasing number of CROs 57
5.2.2 RESTRAINTS 58
5.2.2.1 High implementation cost of imaging systems 58
5.2.3 OPPORTUNITIES 58
5.2.3.1 Developing countries 58
5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals 58
5.2.4 CHALLENGES 59
5.2.4.1 High cost of clinical trials 59
5.3 IMPACT OF COVID-19 ON THE CLINICAL TRIAL IMAGING MARKET 59
5.4 PRICING ANALYSIS 59
TABLE 1 PRICES OF CLINICAL TRIAL IMAGING PRODUCTS (2021) 59
5.5 PATENT ANALYSIS 60
5.6 TRADE ANALYSIS 60
5.6.1 TRADE ANALYSIS FOR X-RAY APPARATUSES 60
TABLE 2 IMPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY,
2016–2020 (USD MILLION) 60
TABLE 3 EXPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY,
2016–2020 (USD MILLION) 61
5.6.2 TRADE ANALYSIS FOR CT APPARATUSES 61
TABLE 4 IMPORT DATA FOR CT APPARATUSES, BY COUNTRY,
2016–2020 (USD MILLION) 61
TABLE 5 EXPORT DATA FOR CT APPARATUSES, BY COUNTRY,
2016–2020 (USD MILLION) 61
5.7 VALUE CHAIN ANALYSIS 62
FIGURE 22 MAJOR VALUE IS ADDED DURING THE DEVELOPMENT AND PROCUREMENT PHASES 62
5.8 SUPPLY CHAIN ANALYSIS 63
FIGURE 23 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES 63
5.9 ECOSYSTEM ANALYSIS OF THE CLINICAL TRIAL IMAGING MARKET 64
FIGURE 24 CLINICAL TRIAL IMAGING MARKET: ECOSYSTEM ANALYSIS 64
5.9.1 ROLE IN THE ECOSYSTEM 64
5.10 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 6 CLINICAL TRIAL IMAGING MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.10.1 THREAT OF NEW ENTRANTS 65
5.10.2 THREAT OF SUBSTITUTES 65
5.10.3 BARGAINING POWER OF BUYERS 65
5.10.4 BARGAINING POWER OF SUPPLIERS 65
5.10.5 DEGREE OF COMPETITION 66
5.11 PESTLE ANALYSIS 66
5.12 REGULATORY LANDSCAPE 67
5.12.1 NORTH AMERICA 67
5.12.1.1 US 67
5.12.1.2 Canada 67
5.12.2 EUROPE 67
5.12.3 ASIA PACIFIC 67
5.12.3.1 Japan 67
5.12.3.2 India 68
5.12.3.3 China 68
5.12.4 LATIN AMERICA 68
5.12.4.1 Brazil 69
5.12.4.2 Mexico 69
5.12.5 MIDDLE EAST 69
5.12.6 AFRICA 69
5.13 TECHNOLOGY ANALYSIS 70
5.14 DISRUPTIVE TECHNOLOGIES IN THE CLINICAL TRIAL IMAGING MARKET 70
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR THE CLINICAL TRIAL IMAGING MARKET 70
FIGURE 25 REVENUE SHIFT FOR THE CLINICAL TRIAL IMAGING MARKET 70
6 CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE 71
6.1 INTRODUCTION 72
TABLE 7 CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 72
TABLE 8 CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 72
6.2 SERVICES 72
TABLE 9 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2016–2019 (USD MILLION) 73
TABLE 10 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2020–2026 (USD MILLION) 73
TABLE 11 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION,
2016–2019 (USD MILLION) 73
TABLE 12 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION,
2020–2026 (USD MILLION) 74
6.2.1 OPERATIONAL IMAGING SERVICES 74
6.2.1.1 The rising number of CROs supports the growth of this segment 74
FIGURE 26 INDUSTRY INSIGHTS ON OPERATIONAL IMAGING SERVICES 74
TABLE 13 OPERATIONAL IMAGING SERVICES MARKET, BY REGION,
2016–2019 (USD MILLION) 75
TABLE 14 OPERATIONAL IMAGING SERVICES MARKET, BY REGION,
2020–2026 (USD MILLION) 75
6.2.2 READ ANALYSIS SERVICES 75
6.2.2.1 Increased number of clinical trials is the major factor supporting the growth of this segment 75
TABLE 15 READ ANALYSIS SERVICES MARKET, BY REGION, 2016–2019 (USD MILLION) 76
TABLE 16 READ ANALYSIS SERVICES MARKET, BY REGION, 2020–2026 (USD MILLION) 76
6.2.3 SYSTEM & TECHNICAL SUPPORT SERVICES 76
6.2.3.1 Need for continuous technical support to drive this segment 76
TABLE 17 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION,
2016–2019 (USD MILLION) 77
TABLE 18 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION,
2020–2026 (USD MILLION) 77
6.2.4 TRIAL DESIGN & CONSULTING SERVICES 77
6.2.4.1 Rising R&D spending and support for clinical trials will prompt companies to outsource trial design processes 77
TABLE 19 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION,
2016–2019 (USD MILLION) 78
TABLE 20 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION,
2020–2026 (USD MILLION) 78
6.3 SOFTWARE 78
6.3.1 HIGH EFFICIENCY AND COST-SAVING BENEFITS OF SOFTWARE SUPPORT ITS ADOPTION 78
TABLE 21 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION,
2016–2019 (USD MILLION) 79
TABLE 22 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION,
2020–2026 (USD MILLION) 79
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY 80
7.1 INTRODUCTION 81
TABLE 23 CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 81
TABLE 24 CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 81
7.2 COMPUTED TOMOGRAPHY 82
7.2.1 QUICK RESULTS AND NO VISIBLE SIDE-EFFECTS DRIVE THE ADOPTION OF CT 82
TABLE 25 CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY,
BY REGION, 2016–2019 (USD MILLION) 82
TABLE 26 CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY,
BY REGION, 2020–2026 (USD MILLION) 83
7.3 MAGNETIC RESONANCE IMAGING 83
7.3.1 INCREASING ADOPTION OF MRI IN ONCOLOGICAL TRIALS AND STUDIES TO DRIVE MARKET GROWTH 83
TABLE 27 CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING,
BY REGION, 2016–2019 (USD MILLION) 84
TABLE 28 CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING,
BY REGION, 2020–2026 (USD MILLION) 84
7.4 ULTRASOUND 84
7.4.1 ULTRASOUND IMAGING IS SAFER THAN CT AND MRI IMAGING 84
TABLE 29 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION,
2016–2019 (USD MILLION) 85
TABLE 30 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION,
2020–2026 (USD MILLION) 85
7.5 POSITRON EMISSION TOMOGRAPHY 85
7.5.1 PET IS A PART OF NUCLEAR MEDICINE IMAGING 85
TABLE 31 CLINICAL TRIAL IMAGING MARKET FOR PET, BY REGION,
2016–2019 (USD MILLION) 86
TABLE 32 CLINICAL TRIAL IMAGING MARKET FOR PET, BY REGION,
2020–2026 (USD MILLION) 86
7.6 X-RAY 87
7.6.1 X-RAY IS MOST COMMONLY USED IN BONE, CHEST, AND DENTAL IMAGING 87
TABLE 33 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION,
2016–2019 (USD MILLION) 87
TABLE 34 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION,
2020–2026 (USD MILLION) 87
7.7 ECHOCARDIOGRAPHY 88
7.7.1 ECHO-DOPPLER PARAMETERS ARE CONSIDERED ACCEPTABLE AS A PROOF OF CONCEPT OF TREATMENT IN PHASE-II TRIALS 88
TABLE 35 CLINICAL TRIAL IMAGING MARKET FOR ECHOCARDIOGRAPHY, BY REGION, 2016–2019 (USD MILLION) 88
TABLE 36 CLINICAL TRIAL IMAGING MARKET FOR ECHOCARDIOGRAPHY, BY REGION, 2020–2026 (USD MILLION) 88
7.8 OTHER MODALITIES 89
TABLE 37 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION, 2016–2019 (USD MILLION) 89
TABLE 38 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION, 2020–2026 (USD MILLION) 90
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 91
8.1 INTRODUCTION 92
TABLE 39 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2016–2019 (USD MILLION) 92
TABLE 40 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2016–2019 (USD MILLION) 93
TABLE 42 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION,
2020–2026 (USD MILLION) 94
8.3 INFECTIOUS DISEASES 94
8.3.1 RISING DRUG DISCOVERY ACTIVITY SUPPORTS MARKET GROWTH 94
TABLE 43 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016–2019 (USD MILLION) 94
TABLE 44 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2026 (USD MILLION) 95
8.4 NEUROLOGY 95
8.4.1 GROWING INVESTMENTS IN CNS DISORDER RESEARCH TO DRIVE SEGMENT GROWTH 95
TABLE 45 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION,
2016–2019 (USD MILLION) 96
TABLE 46 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION,
2020–2026 (USD MILLION) 96
8.5 CARDIOVASCULAR SYSTEM DISORDERS 96
8.5.1 HIGH MORTALITY RATE OF CVD HAS DRIVEN FOCUS ON THERAPEUTICS AND CLINICAL TRIALS 96
TABLE 47 CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2016–2019 (USD MILLION) 97
TABLE 48 CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2020–2026 (USD MILLION) 97
8.6 ENDOCRINOLOGY 97
8.6.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET GROWTH 97
TABLE 49 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION, 2016–2019 (USD MILLION) 98
TABLE 50 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION, 2020–2026 (USD MILLION) 98
8.7 IMMUNOLOGICAL DISORDERS 99
8.7.1 ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES ARE HIGHLY COMMON AILMENTS GLOBALLY 99
TABLE 51 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS,
BY REGION, 2016–2019 (USD MILLION) 99
TABLE 52 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS,
BY REGION, 2020–2026 (USD MILLION) 99
8.8 OTHER THERAPEUTIC AREAS 100
TABLE 53 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2016–2019 (USD MILLION) 100
TABLE 54 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2020–2026 (USD MILLION) 101
9 CLINICAL TRIAL IMAGING MARKET, BY END USER 102
9.1 INTRODUCTION 103
TABLE 55 CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 103
TABLE 56 CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 103
9.2 PHARMACEUTICAL COMPANIES 104
9.2.1 INCREASING R&D ACTIVITIES BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH FOR THIS SEGMENT 104
TABLE 57 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL COMPANIES,
BY REGION, 2016–2019 (USD MILLION) 104
TABLE 58 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL COMPANIES,
BY REGION, 2020–2026 (USD MILLION) 105
9.3 BIOTECHNOLOGY COMPANIES 105
9.3.1 RISING R&D BUDGETS OF BIOTECH COMPANIES TO DRIVE GROWTH 105
TABLE 59 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2019–2020 106
TABLE 60 CLINICAL TRIAL IMAGING MARKET FOR BIOTECHNOLOGY COMPANIES,
BY REGION, 2016–2019 (USD MILLION) 106
TABLE 61 CLINICAL TRIAL IMAGING MARKET FOR BIOTECHNOLOGY COMPANIES,
BY REGION, 2020–2026 (USD MILLION) 107
9.4 MEDICAL DEVICE MANUFACTURERS 107
9.4.1 INCREASING R&D SPENDING BY MEDICAL DEVICES MANUFACTURERS TO DRIVE MARKET GROWTH 107
TABLE 62 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2016–2019 (USD MILLION) 108
TABLE 63 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2020–2026 (USD MILLION) 108
9.5 CONTRACT RESEARCH ORGANIZATIONS 108
9.5.1 INCREASING TREND OF OUTSOURCING TO DRIVE MARKET GROWTH 108
TABLE 64 CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2016–2019 (USD MILLION) 109
TABLE 65 CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2026 (USD MILLION) 110
9.6 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 110
9.6.1 INCREASING RESEARCH ACTIVITIES TO DRIVE MARKET GROWTH 110
TABLE 66 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2016–2019 (USD MILLION) 111
TABLE 67 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET, BY REGION, 2020–2026 (USD MILLION) 111
9.7 OTHER END USERS 112
TABLE 68 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION, 2016–2019 (USD MILLION) 112
TABLE 69 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION, 2020–2026 (USD MILLION) 112
10 CLINICAL TRIAL IMAGING MARKET, BY REGION 113
10.1 INTRODUCTION 114
TABLE 70 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2016–2019 (USD MILLION) 114
TABLE 71 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020–2026 (USD MILLION) 114
10.2 NORTH AMERICA 115
FIGURE 27 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 115
TABLE 72 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2016–2019 (USD MILLION) 116
TABLE 73 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 116
TABLE 74 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 116
TABLE 75 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 117
TABLE 76 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 117
TABLE 77 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 117
TABLE 78 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 118
TABLE 79 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 118
10.2.1 US 118
10.2.1.1 Increased investment in the biopharmaceutical industry in the US to favor market growth 118
TABLE 80 US: PRODUCT APPROVALS IN THE CLINICAL TRIAL IMAGING SPACE 119
TABLE 81 US: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 119
TABLE 82 US: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 119
TABLE 83 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 120
TABLE 84 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 120
TABLE 85 US: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 121
TABLE 86 US: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 121
10.2.2 CANADA 121
10.2.2.1 Increase in per capita healthcare spending to drive the clinical trial imaging market in Canada 121
TABLE 87 CANADA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 122
TABLE 88 CANADA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 122
TABLE 89 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 122
TABLE 90 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 123
TABLE 91 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 123
TABLE 92 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 123
10.3 EUROPE 124
TABLE 93 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2016–2019 (USD MILLION) 124
TABLE 94 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 124
TABLE 95 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 125
TABLE 96 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 125
TABLE 97 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 125
TABLE 98 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 126
TABLE 99 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 126
TABLE 100 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 126
10.3.1 GERMANY 127
10.3.1.1 Germany is the largest & fastest-growing market for clinical trial imaging in Europe 127
TABLE 101 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 127
TABLE 102 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 127
TABLE 103 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 128
TABLE 104 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 128
TABLE 105 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 129
TABLE 106 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 129
10.3.2 UK 129
10.3.2.1 Rising research investments to drive the market growth in the UK 129
TABLE 107 UK: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 130
TABLE 108 UK: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 130
TABLE 109 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 130
TABLE 110 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 131
TABLE 111 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 131
TABLE 112 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 131
10.3.3 FRANCE 132
10.3.3.1 Rising R&D expenditure to drive market growth in France 132
TABLE 113 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 132
TABLE 114 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 132
TABLE 115 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 133
TABLE 116 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 133
TABLE 117 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 134
TABLE 118 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 134
10.3.4 ITALY 134
10.3.4.1 Increase R&D spending on healthcare to drive market growth in this region 134
TABLE 119 ITALY: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 135
TABLE 120 ITALY: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 135
TABLE 121 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 135
TABLE 122 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 136
TABLE 123 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 136
TABLE 124 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 136
10.3.5 SPAIN 137
10.3.5.1 Growth of pharmaceutical companies 137
TABLE 125 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 137
TABLE 126 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 137
TABLE 127 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 138
TABLE 128 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 138
TABLE 129 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 139
TABLE 130 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 139
10.3.6 REST OF EUROPE 139
TABLE 131 ROE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 140
TABLE 132 ROE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 140
TABLE 133 ROE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 140
TABLE 134 ROE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 141
TABLE 135 ROE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 141
TABLE 136 ROE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 141
10.4 ASIA PACIFIC 142
FIGURE 28 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 142
TABLE 137 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2016–2019 (USD MILLION) 143
TABLE 138 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 143
TABLE 139 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 143
TABLE 140 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 144
TABLE 141 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 144
TABLE 142 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 144
TABLE 143 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 145
TABLE 144 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 145
10.4.1 CHINA 145
10.4.1.1 Increase in research spending to drive market growth 145
TABLE 145 CHINA: KEY MACROINDICATORS 146
TABLE 146 CHINA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 146
TABLE 147 CHINA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 146
TABLE 148 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 147
TABLE 149 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 147
TABLE 150 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 148
TABLE 151 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 148
10.4.2 JAPAN 148
10.4.2.1 Rising population and healthcare expenditure are favorable factors in Japan 148
TABLE 152 JAPAN: KEY MACROINDICATORS 149
TABLE 153 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 149
TABLE 154 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 149
TABLE 155 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 150
TABLE 156 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 150
TABLE 157 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 151
TABLE 158 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 151
10.4.3 INDIA 151
10.4.3.1 Increased investment in R&D to drive the adoption of clinical trial imaging 151
TABLE 159 INDIA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 152
TABLE 160 INDIA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 152
TABLE 161 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 153
TABLE 162 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 153
TABLE 163 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 154
TABLE 164 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 154
10.4.4 REST OF ASIA PACIFIC 154
TABLE 165 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 155
TABLE 166 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 155
TABLE 167 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 155
TABLE 168 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 156
TABLE 169 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY END USER
, 2016–2019 (USD MILLION) 156
TABLE 170 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 156
10.5 LATIN AMERICA 157
10.5.1 INCREASING R&D DUE TO DISEASE OUTBREAKS TO SUPPORT MARKET GROWTH 157
TABLE 171 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 157
TABLE 172 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 157
TABLE 173 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 158
TABLE 174 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 158
TABLE 175 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 159
TABLE 176 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 159
10.6 MIDDLE EAST & AFRICA 160
10.6.1 INCREASED FUNDING AND PARTNERSHIPS IN THE RESEARCH SECTOR TO PROPEL MARKET GROWTH 160
TABLE 177 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 160
TABLE 178 MIDDLE EAST AND AFRICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 160
TABLE 179 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2016–2019 (USD MILLION) 161
TABLE 180 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020–2026 (USD MILLION) 161
TABLE 181 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2016–2019 (USD MILLION) 162
TABLE 182 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020–2026 (USD MILLION) 162
11 COMPETITIVE LANDSCAPE 163
11.1 OVERVIEW 163
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 163
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE CLINICAL TRIAL IMAGING MARKET 163
TABLE 183 OVERVIEW OF STRATEGIES DEPLOYED BY KEY CLINICAL TRIAL IMAGING PRODUCT MANUFACTURING COMPANIES 163
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 165
FIGURE 29 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE CLINICAL TRIAL IMAGING MARKET 165
11.4 MARKET SHARE ANALYSIS 166
FIGURE 30 CLINICAL TRIAL IMAGING MARKET SHARE, BY KEY PLAYER (2020) 166
TABLE 184 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION 166
11.5 COMPANY EVALUATION QUADRANT 167
11.5.1 STARS 167
11.5.2 EMERGING LEADERS 167
11.5.3 PERVASIVE PLAYERS 167
11.5.4 PARTICIPANTS 167
FIGURE 31 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION QUADRANT, 2020 168
11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020) 168
11.6.1 PROGRESSIVE COMPANIES 168
11.6.2 STARTING BLOCKS 169
11.6.3 RESPONSIVE COMPANIES 169
11.6.4 DYNAMIC COMPANIES 169
FIGURE 32 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020 169
11.7 COMPETITIVE BENCHMARKING 170
FIGURE 33 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CLINICAL TRIAL IMAGING MARKET 170
TABLE 185 COMPANY PRODUCT FOOTPRINT 170
TABLE 186 COMPANY GEOGRAPHICAL FOOTPRINT 170
11.8 COMPETITIVE SCENARIO 171
11.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS 171
TABLE 187 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS 171
11.8.2 DEALS 171
TABLE 188 KEY DEALS 171
12 COMPANY PROFILES 172
12.1 KEY PLAYERS 172
(Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats)*
12.1.1 ICON PLC. 172
TABLE 189 ICON PLC.: BUSINESS OVERVIEW 172
FIGURE 34 ICON PLC.: COMPANY SNAPSHOT (2020) 172
12.1.2 BIOTELEMETRY INC. 175
TABLE 190 BIOTELEMETRY INC.: BUSINESS OVERVIEW 175
FIGURE 35 PHILIPS GROUP: COMPANY SNAPSHOT (2020) 175
12.1.3 BIOMEDICAL SYSTEMS CORPORATION (A PART OF ERT CLINICAL) 177
TABLE 191 BIOMEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW 177
12.1.4 MEDPACE HOLDINGS INC. 178
TABLE 192 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW 178
FIGURE 36 MEDPACE HOLDINGS INC.: COMPANY SNAPSHOT (2020) 178
12.1.5 IXICO PLC. 180
TABLE 193 IXICO PLC.: BUSINESS OVERVIEW 180
FIGURE 37 IXICO PLC.: COMPANY SNAPSHOT (2020) 180
12.1.6 RESONANCE HEALTH LTD. 183
TABLE 194 RESONANCE HEALTH LTD.: BUSINESS OVERVIEW 183
FIGURE 38 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT (2020) 183
12.1.7 RADIANT SAGE 186
TABLE 195 RADIANT SAGE: BUSINESS OVERVIEW 186
12.1.8 BIOCLINICA INC. 187
TABLE 196 BIOCLINICA: BUSINESS OVERVIEW 187
12.1.9 INTRINSIC IMAGING 189
TABLE 197 INTRINSIC IMAGING: BUSINESS OVERVIEW 189
12.1.10 CARDIOVASCULAR IMAGING TECHNOLOGIES 190
TABLE 198 CARDIOVASCULAR IMAGING TECHNOLOGIES: BUSINESS OVERVIEW 190
12.2 OTHER PLAYERS 191
12.2.1 MEDICAL METRICS 191
12.2.2 PRISM CLINICAL IMAGING 191
12.2.3 BOSTON IMAGING CORE LAB 192
12.2.4 ANAGRAM 4 CLINICAL TRIALS 192
12.2.5 LYSCAUT MEDICAL IMAGING COMPANY 193
12.2.6 CALYX GROUP 193
12.2.7 BIOSPECTIVE 194
12.2.8 PROSCAN IMAGING 194
12.2.9 MICRON 195
12.2.10 IMAGING ENDPOINTS LI LLC. 196
12.2.11 PERSPECTUM 196
12.2.12 PHARMTRACE KLINISCHE ENTWICKLUNG 197
12.2.13 WORLDCARE CLINICAL 197
*Details on Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats might not be captured in case of unlisted companies.
13 APPENDIX 198
13.1 INDUSTRY INSIGHTS 198
13.2 DISCUSSION GUIDE 199
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 203
13.4 AVAILABLE CUSTOMIZATIONS 205
13.5 RELATED REPORTS 205
13.6 AUTHOR DETAILS 206

Lateral Flow Assay Components Market by Type, Application Type (Clinical Testing (Infectious, Cardiac Marker Test) Veterinary, Food Safety), Technique...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  April, 2022

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
 
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
 
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232

US Healthcare Environmental Services Market by Type (Janitorial/Core-Cleaning, Infection Control & Prevention, Front-of-house cleaning & Brand Experie...

Publisher:        MarketsandMarkets

# of Pages:        126

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION & SCOPE 15
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 16
1.2.2 MARKET SEGMENTATION 16
FIGURE 1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET SEGMENTATION 16
1.2.3 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 17
1.4 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
FIGURE 2 RESEARCH DESIGN 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 21
FIGURE 3 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Insights from primary experts 23
2.1.2.3 Breakdown of primary interviews 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE (SUPPLY & DEMAND SIDE) AND DESIGNATION 24
2.2 MARKET SIZE ESTIMATION 25
FIGURE 5 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 25
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 26
FIGURE 7 DEMAND-SIDE APPROACH 28
2.3 DATA TRIANGULATION 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 29
2.4 MARKET RANKING ANALYSIS 30
2.5 ASSUMPTIONS FOR THE STUDY 30
2.6 LIMITATIONS 31
2.6.1 METHODOLOGY-RELATED LIMITATIONS 31
2.6.2 SCOPE-RELATED LIMITATIONS 31
2.7 RISK ASSESSMENT 31
TABLE 2 RISK ASSESSMENT: US HEALTHCARE ENVIRONMENTAL SERVICES MARKET 31
 
3 EXECUTIVE SUMMARY 32
FIGURE 9 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 32
FIGURE 10 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET,
BY FACILITY TYPE, 2021 VS. 2026 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET OVERVIEW 34
FIGURE 11 STRINGENT REGULATORY GUIDELINES ON INFECTION CONTROL & PREVENTION METHODS IS A KEY FACTOR DRIVING THE MARKET GROWTH 34
4.2 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE AND FACILITY TYPE 35
FIGURE 12 JANITORIAL/CORE-CLEANING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE US HEALTHCARE ENVIRONMENTAL SERVICES
MARKET IN 2020 35
4.3 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE (2021–2026) 36
FIGURE 13 ACUTE CARE FACILITIES TO DOMINATE THE US HEALTHCARE ENVIRONMENTAL SERVICES MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
TABLE 3 MARKET DYNAMICS: HEALTHCARE ENVIRONMENTAL SERVICES MARKET 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing prevalence of Hospital-acquired infections (HAIs) 38
5.2.1.2 Rising number of hospital admissions and surgeries 39
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED 39
FIGURE 14 TOTAL ADMISSIONS IN ALL US HOSPITALS 40
FIGURE 15 TOTAL NUMBER OF HOSPITALS IN THE US 40
5.2.1.3 Shortage of in-house expertise and the rising need to reduce healthcare costs 41
5.2.1.4 Increasing outsourcing of cleaning services 41
5.2.2 MARKET RESTRAINTS 41
5.2.2.1 Healthcare facilities with an in-house EVS department 41
5.2.3 MARKET OPPORTUNITIES 42
5.2.3.1 Sustained acquisitions among strategic & financial buyers 42
TABLE 5 COMPANY ACQUISITIONS 42
5.2.4 MARKET CHALLENGES 42
5.2.4.1 Noncompliance with cleaning standards by EVS providers 42
5.3 INDUSTRY TRENDS 43
5.3.1 EMERGENCE OF NEW SURFACE DISINFECTANTS &
GREEN CLEANING PRODUCTS 43
5.3.2 DISINFECTION ROBOTS 44
5.3.3 MONITORING TOOLS FOR CLEANING QUALITY ASSESSMENT 44
5.4 TECHNOLOGY ANALYSIS 45
TABLE 6 TECHNOLOGY INNOVATION IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 45
5.5 PATENT ANALYSIS 45
5.5.1 PATENT PUBLICATION TRENDS FOR HEALTHCARE ENVIRONMENTAL SERVICES 46
FIGURE 16 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 46
5.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 47
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 47
FIGURE 18 TOP APPLICANT COUNTRIES/REGIONS FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 48
TABLE 7 LIST OF PATENTS/PATENT APPLICATIONS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET, 2020–2021 48
5.6 IMPACT OF COVID-19 ON THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 50
6 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE 51
6.1 INTRODUCTION 52
TABLE 8 US: HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 52
6.2 JANITORIAL SERVICES/CORE-CLEANING SERVICES 52
6.2.1 MANDATORY REGULAR CLEANING AND DISINFECTION OF HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH 52
6.3 INFECTION PREVENTION & CONTROL SERVICES 53
TABLE 9 US: INFECTION PREVENTION & CONTROL SERVICE MARKET, BY TYPE,
2019–2026 (USD MILLION) 53
6.3.1 SPECIALIZED CLEANING SERVICES 53
6.3.1.1 Rising adoption of specialized services to reduce HAIs to drive the market growth 53
6.3.2 INFECTION PREVENTION & CONTROL CONSULTATION SERVICES 53
6.3.2.1 The provision of customized environmental services specific
to a healthcare facility ensures market demand 53
6.4 ENHANCED CLEANING TECHNOLOGY 54
6.4.1 RISING DEMAND FOR ADVANCED CLEANING SOLUTIONS TO DRIVE THE SEGMENT GROWTH 54
TABLE 10 EXAMPLES OF COMPANIES PROVIDING TECHNOLOGY & INNOVATION IN HEALTHCARE EVS 54
6.5 FRONT-OF-HOUSE CLEANING AND BRAND EXPERIENCE 56
6.5.1 RISING AWARENESS TOWARDS A CLEAN AND SAFE ENVIRONMENT DURING PANDEMICS TO SUSTAIN THE MARKET GROWTH 56
6.6 OTHER SERVICES 56
 
7 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE 57
7.1 INTRODUCTION 58
FIGURE 19 STATES WITH THE HIGHEST NUMBER OF COVID-19 ADMISSIONS
(FEBRUARY 2022) 58
TABLE 11 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE, 2019–2026 (USD MILLION) 59
7.2 ACUTE-CARE FACILITIES 59
TABLE 12 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR ACUTE-CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 59
7.2.1 ACUTE HOSPITALS 60
7.2.1.1 Increasing hospital admissions due to COVID-19 and the rising prevalence of HAIs propel the market growth 60
FIGURE 20 NUMBER OF HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS
IN THE US (2020) 60
FIGURE 21 HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS IN THE US (2020) 61
FIGURE 22 HAIS REPORTED BY CRITICAL ACCESS HOSPITALS (CAHS) IN THE US (2018) 61
7.2.2 MILITARY TREATMENT FACILITY 61
7.2.2.1 The increasing number of military ambulatory health services & funding to drive the market growth 61
FIGURE 23 MILITARY HEALTH SYSTEMS FACILITIES IN THE US (2021) 62
7.2.3 CHILDREN’S HOSPITALS 62
7.2.3.1 Rising cases of COVID-19 and infection-related mortality rates among children drive the market growth 62
7.2.4 AMBULATORY SURGERY CENTERS (ASCS) 63
7.2.4.1 ASCs save time and reduce the risk of HAIS; key factor driving the market growth 63
FIGURE 24 US SURGERY CASES BY SETTING: ASC VS. HOPD (2005-2020) 64
7.2.5 ACADEMIC MEDICAL CENTERS (AMCS) 64
7.2.5.1 Healthcare capacity expansion during COVID-19 drives the adoption of healthcare environmental services in AMCs 64
7.3 POST-ACUTE CARE FACILITIES 64
TABLE 13 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR POST-ACUTE CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 65
7.3.1 LONG-TERM ACUTE HOSPITALS (LTACH) 65
7.3.1.1 Increasing risk of infection due to prolonged hospital stays to drive the market growth 65
7.3.2 SKILLED NURSING FACILITIES (SNF) 66
7.3.2.1 Increasing admissions of elderly people in skilled nursing facilities to drive the market growth 66
7.3.3 OTHER POST-ACUTE CARE FACILITIES 66
7.4 NON-ACUTE CARE FACILITIES 67
TABLE 14 US: ENVIRONMENTAL SERVICES MARKET FOR NON-ACUTE CARE SETTINGS, BY TYPE, 2019–2026 (USD MILLION) 67
7.4.1 PHYSICIAN’S OFFICES AND CLINICS 67
7.4.1.1 High patient traffic leads to continuous cleaning & maintenance to drive the market growth 67
7.4.2 OTHER NON-ACUTE CARE FACILITIES 68
FIGURE 25 DISTRIBUTION OF INDUSTRY MEDICAL AND HEALTH R&D INVESTMENTS,
BY SEGMENT (2020) 68
8 COMPETITIVE LANDSCAPE 70
8.1 OVERVIEW 70
8.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 70
8.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 71
8.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 72
8.4 MARKET RANKING ANALYSIS 73
FIGURE 27 US HEALTHCARE ENVIRONMENTAL SERVICE MARKET RANKING,
BY KEY PLAYER, 2020 73
8.5 COMPETITIVE BENCHMARKING 75
TABLE 15 FOOTPRINT OF COMPANIES IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 75
TABLE 16 SERVICE FOOTPRINT OF COMPANIES 76
TABLE 17 END-USER FOOTPRINT OF COMPANIES 77
8.6 COMPETITIVE LEADERSHIP MAPPING 77
8.6.1 STARS 78
8.6.2 EMERGING LEADERS 78
8.6.3 PERVASIVE PLAYERS 78
8.6.4 PARTICIPANTS 78
FIGURE 28 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET:
COMPETITIVE LEADERSHIP MAPPING (2021) 79
8.7 COMPETITIVE SCENARIO 80
8.7.1 SERVICE APPROVALS/ENHANCEMENTS 80
8.7.2 DEALS 81
TABLE 19 DEALS, 2018–2022 81
8.7.3 OTHER DEVELOPMENTS 82
9 COMPANY PROFILES 83
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 SODEXO GLOBAL 83
TABLE 21 SODEXO GLOBAL: BUSINESS OVERVIEW 83
FIGURE 29 SODEXO GLOBAL: COMPANY SNAPSHOT (2021) 84
9.2 COMPASS GROUP (CROTHALL HEALTHCARE (US)) 87
TABLE 22 COMPASS GROUP: BUSINESS OVERVIEW 87
FIGURE 30 COMPASS GROUP: COMPANY SNAPSHOT (2021) 88
 
9.3 ARAMARK CORPORATION 90
TABLE 23 ARAMARK CORPORATION: BUSINESS OVERVIEW 90
FIGURE 31 ARAMARK CORPORATION: COMPANY SNAPSHOT (2021) 91
9.4 HOSPITAL HOUSEKEEPING SYSTEMS (HHS) (US) 94
TABLE 24 HOSPITAL HOUSEKEEPING SYSTEMS (HHS): BUSINESS OVERVIEW 94
9.5 HEALTHCARE SERVICES GROUP, INC. 97
TABLE 25 HEALTHCARE SERVICES GROUP, INC.: BUSINESS OVERVIEW 97
FIGURE 32 HEALTHCARE SERVICES GROUP: COMPANY SNAPSHOT (2020) 98
9.6 ABM INDUSTRIES INCORPORATED 100
TABLE 26 ABM INDUSTRIES INCORPORATED: BUSINESS OVERVIEW 100
FIGURE 33 ABM INDUSTRIES INCORPORATED: COMPANY SNAPSHOT (2020) 101
9.7 OCTOCLEAN 103
TABLE 27 OCTOCLEAN: BUSINESS OVERVIEW 103
9.8 SERVICEMASTER CLEAN (SERVICEMASTER TBS) 105
TABLE 28 SERVICEMASTER CLEAN.: BUSINESS OVERVIEW 105
9.9 CORVUS JANITORIAL SYSTEMS 107
TABLE 29 CORVUS JANITORIAL SYSTEMS: BUSINESS OVERVIEW 107
9.10 BRAVO! BUILDING SERVICES 109
TABLE 30 BRAVO! BUILDING SERVICES: BUSINESS OVERVIEW 109
9.11 POWERLINK ENVIRONMENTAL SERVICES, LLC 111
TABLE 31 POWERLINK ENVIRONMENTAL SERVICES, LLC: BUSINESS OVERVIEW 111
9.12 JANI-KING INTERNATIONAL, INC. 112
TABLE 32 JANI- KING INTERNATIONAL, INC: BUSINESS OVERVIEW 112
9.13 AVI FOOD SYSTEMS(US) 114
TABLE 33 AVI FOOD SYTEMS, INC.: BUSINESS OVERVIEW 114
9.14 SERVICON 115
TABLE 34 SERVICON: BUSINESS OVERVIEW 115
9.15 XANITOS, INC. 117
TABLE 35 XANITOS, INC.: BUSINESS OVERVIEW 117
9.16 STATHAKIS 119
TABLE 36 STATHAKIS: BUSINESS OVERVIEW 119
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 120
10.1 INSIGHTS FROM INDUSTRY EXPERTS 120
10.2 DISCUSSION GUIDE 121
10.3 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 124
10.4 AVAILABLE CUSTOMIZATIONS 126
10.5 RELATED REPORTS 126
10.6 AUTHOR DETAILS 127